+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Plasma Fractionation Market by Product, Sector: Global Opportunity Analysis and Industry Forecast, 2020-2027

  • ID: 5157241
  • Report
  • August 2020
  • Region: Global
  • 208 pages
  • Allied Analytics LLP
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The global plasma fractionation market accounted for $18,222 million in 2019, and is expected to reach $23,006 million by 2027, registering a CAGR of 6.2% from 2020 to 2027. Fractionation is a mechanical process carried out to separate a certain quantity of mixture. Plasma is the liquid part of blood which is yellowish and holds blood cells. Plasma fractionation is carried out to separate high quality, proteinaceous products such as albumin and immunoglobulins. These derived products are known as plasma derivatives obtained from fractionation. Moreover, these products is used in various medical fields such as in neurology, hematology, critical care, and immunology. For instance, in critical care, plasma is prescribed to prevent and stop bleeding. In addition, plasma products are widely used in clinical research laboratories and hospitals. In addition, there are majorly two types of players that conduct plasma fractionation such as public players and private players. Moreover, public players include the companies which are non-profit government run bodies that fractionate plasma. Similarly, private players include the companies which earn profit by the sale of fractionated plasma products.

Surge in geriatric population across the globe, which is predisposed to various rare diseases that require use of plasma derivatives is the major factor that boosts the market growth. Moreover, rise in use of immunoglobulins and alpha-1-antitrypsin in areas of medicine worldwide also fuels growth of the plasma fractionation market. Furthermore, surge in plasma collection centers worldwide is another major factor that contributes toward growth of this market.

In addition, favorable government support to spread awareness related to use of plasma derived products also fuels growth of the plasma fractionation market. However, fractionation is an expensive procedure, which includes collection of pooled blood from a large group of individuals. These individuals undergo screening to detect and avoid diseases, which can be transmitted through plasma. Furthermore, plasma-derived products are further screened post formulation to destroy any bacteria and viruses present in the product. These steps, in turn, make plasma derived products expensive which serves as a hindrance to the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period. Furthermore, there are advancements in processes, improved formulations, and increase in production efficiency. Advancement in technology leads to improved process of plasma manufacturing, hence leading to growth of the market
The global plasma fractionation market is segmented on the basis of product, sector, and country. On the basis of product, the market is divided into albumin, immunoglobulins, coagulation factor VIII, and coagulation factor IX. By sector, the market is classified into public sector and private sector. By country, it is analyzed across Turkey, Russia, Korea, Kingdom of Saudi Arabia, Taiwan, Indonesia, Thailand, Malaysia, Canada, Vietnam and rest of the world.

The global plasma fractionation market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum plasma fractionation market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Grifols SA, Baxter International Inc, CSL LTD., Bio Product Laboratory, Octapharma AG, Sanquin, Laboratoire Franais Du Fractionnement Et Des Biotechnologies, Kedrion, Biotest, and Takeda Pharmaceuticals.

Key Benefits for Stakeholders
  • This report entails a detailed quantitative analysis along with the current global plasma fractionation market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments

By Product
  • Albumin
  • Immunoglobulin
  • Coagulation Factor VIII
  • Coagulation Factor IX
By Sector
  • Public Sector
  • Private Sector
By Country
  • Turkey
  • Russia
  • South Korea
  • Saudi Arabia
  • Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Canada
  • Vietnam
  • Rest of the World
List of key players profiled in the report:
  • Grifols SA
  • Baxter International Inc
  • CSL LTD.
  • Bio Product Laboratory
  • Octapharma AG
  • Sanquin
  • Laboratoire Franais Du Fractionnement Et Des Biotechnologies
  • Kedrion
  • Biotest
  • Takeda Pharmaceuticals
LIST OF OTHER PLAYERS IN THE VALUE CHAIN(These players are not profiled in the report. The same will be included on request)
  • China Biologic Products
  • China Biologic Products.
Note: Product cover images may vary from those shown
2 of 3
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled in the Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models

Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. Cxo Perspective

Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Buyers
3.3.2. Bargaining Power of Suppliers
3.3.3. Thereat of New Entrants
3.3.4. Threat of Substitutes
3.3.5. Intensity of Competitive Rivalry
3.4. Top Player Positioning, 2019
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Surge in Geriatric Population Across, Coupled With Rise in Prevalence of Rare Diseases
3.5.1.2. Rise in Use of Immunoglobulins in Medicine
3.5.1.3. Increase in Number of Plasma Collection Centers Across the Globe
3.5.2. Restraint
3.5.2.1. High Cost of Plasma Derived Products
3.5.3. Opportunity
3.5.3.1. High Growth Potential in Emerging Economies
3.5.4. Impact Analysis

Chapter 4: Plasma Fractionation Market, by Product
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Albumin
4.2.1. Key Market Trends and Growth Opportunities
4.2.2. Market Size and Forecast, by Country
4.3. Immunoglobulins
4.3.1. Key Market Trends and Growth Opportunities
4.3.2. Market Size and Forecast, by Country
4.4. Coagulation Factor Viii
4.4.1. Key Market Trends and Growth Opportunities
4.4.2. Market Size and Forecast, by Country
4.5. Coagulation Factor Ix
4.5.1. Key Market Trends and Growth Opportunities
4.5.2. Market Size and Forecast, by Country

Chapter 5: Plasma Fractionation Market, by Sector
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Public Sector
5.2.1. Market Size and Forecast, by Region
5.3. Private Sector
5.3.1. Market Size and Forecast, by Country

Chapter 6: Plasma Fractionation Market, by Country
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Turkey
6.2.1. Key Market Trends and Growth Opportunities
6.2.2. Market Size and Forecast, by Product
6.2.3. Market Size and Forecast, by Sector
6.3. Russia
6.3.1. Key Market Trends and Growth Opportunities
6.3.2. Market Size and Forecast, by Product
6.3.3. Market Size and Forecast, by Sector
6.4. Korea (South Korea)
6.4.1. Key Market Trends and Growth Opportunities
6.4.2. Market Size and Forecast, by Product
6.4.3. Market Size and Forecast, by Sector
6.5. Kingdom of Saudi Arabia
6.5.1. Key Market Trends and Growth Opportunities
6.5.2. Market Size and Forecast, by Product
6.5.3. Market Size and Forecast, by Sector
6.6. Taiwan
6.6.1. Key Market Trends and Growth Opportunities
6.6.2. Market Size and Forecast, by Product
6.6.3. Market Size and Forecast, by Sector
6.7. Indonesia
6.7.1. Key Market Trends and Growth Opportunities
6.7.2. Market Size and Forecast, by Product
6.7.3. Market Size and Forecast, by Sector
6.8. Thailand
6.8.1. Key Market Trends and Growth Opportunities
6.8.2. Market Size and Forecast, by Product
6.8.3. Market Size and Forecast, by Sector
6.9. Malaysia
6.9.1. Key Market Trends and Growth Opportunities
6.9.2. Market Size and Forecast, by Product
6.9.3. Market Size and Forecast, by Sector
6.10. Canada
6.10.1. Key Market Trends and Growth Opportunities
6.10.2. Market Size and Forecast, by Product
6.10.3. Market Size and Forecast, by Sector
6.11. Vietnam
6.11.1. Key Market Trends and Growth Opportunities
6.11.2. Market Size and Forecast, by Product
6.11.3. Market Size and Forecast, by Sector
6.12. Rest of the World
6.12.1. Key Market Trends and Growth Opportunities
6.12.2. Market Size and Forecast, by Product
6.12.3. Market Size and Forecast, by Sector

Chapter 7: Company Profiles
7.1. Baxter International Inc.
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Bio Products Laboratory
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Key Strategic Moves and Developments
7.3. Biotest AG
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.3.6. Key Strategic Moves and Developments
7.4. Csl Ltd.
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.4.6. Key Strategic Moves and Developments
7.5. Grifols Sa
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.5.6. Key Strategic Moves and Developments
7.6. Kedrion S. P. A. (Kedrion Biopharma Inc.)
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Lfb S. A
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.8. Octapharma AG
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.8.6. Key Strategic Moves and Developments
7.9. Sanquin Blood Supply Foundation
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.9.6. Key Strategic Moves and Developments
7.10. Takeda Pharmaceutical Company Limited
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
7.10.6. Key Strategic Moves and Developments
Note: Product cover images may vary from those shown
3 of 3

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll